»
Antibodies
»
anti-Tumor Necrosis Factor Receptor Superfamily, Member 10a (TNFRSF10A) antibody
Tumor Necrosis Factor Receptor Superfamily, Member 10a (TNFRSF10A) antibody
| Antigen |
|
| Synonyms |
DR4, APO2, CD261, MGC9365, TRAILR1, TRAILR-1, TNFRSF10A |
| Clonality |
Monoclonal (DR-4-02) |
|
Host
|
|
|
Reactivity
|
|
|
Application
|
Alternatives Flow Cytometry (FACS), Immunoprecipitation (IP), Functional Studies (Func), Immunocytochemistry (ICC)
|
| Catalog no. |
ABIN94303 |
| Quantity |
0.1 mg (1 mg/ml) |
| Price |
325.00 $ Plus shipping costs $35.00
|
| Shipping to |
|
| Availability |
Ships within 3 to 5 Business Days |
|
Alternative name
|
CD261 / TRAIL-R1
|
|
Immunogen
|
Fusion protein containing the extracellular part of TRAIL-R1 and the constant part of theheavy chain of the human IgG1.
|
|
Format
|
Azide Free
|
|
Isotype
|
IgG1 (Matching secondary antibodies)
|
|
Clone
|
DR-4-02
|
|
Description
|
TRAIL-R1 (CD261, DR4) is a type I transmembrane protein, also called TRAIL receptor 1.The ligand for this DR4 death receptor has been identified and termed TRAIL, which is amember of the TNF family. DR4, as many other receptors (Fas, TNFR1, etc.), mediatesapoptosis and NF kappaB activation in many cells and tissues.Apoptosis, a programmed cell death, is a operating process in normal cellulardifferentiation and development of multicellular organisms. Apoptosis is induced by coupledof certain cytokines (TNF family - TNF, Fas ligand) and their death domain containingreceptors (TNFR1, Fas receptor).
|
|
Specificity
|
The antibody DR-4-02 recognizes TRAIL-R1 (DR4), a human death receptor 4 (468 aminoacids) expressed in most human tissues (spleen, peripheral blood leucocytes, thymus) andin a variety of tumour-derived cell lines.
|
|
Application Notes
|
Flow Cytometry: Recommended dilution: 3-5 µg/ml ImmunoprecipitationImmunocytochemistryFunctional ApplicationSoluble antibody DR-4-02 blocks apoptosis triggered by a ligand (TRAIL). Plastic-immobilized (cross-linked) DR-4-02 antibody induces apoptosis in sensitive cells. Recommended dilution of antibody: 2-3 µg/ml in cultivation medium Final concentration of TRAIL: 20-200 ng/ml. Application note: It is recommended to add the antibody 15 min before addition of TRAIL.
|
|
Concentration
|
1 mg/ml
|
|
Purity
|
> 95% (by SDS-PAGE)
|
|
Purification
|
Purified from hybridoma culture supernatant by protein A-affinity chromatography.
|
|
Buffer
|
Azide free phosphate buffered saline (PBS), approx. pH 7.4, 0.2 µ m filter sterilized.
|
|
Storage
|
Store at 2-8 o C. Do not use after expiration date stamped on vial label. For long-term storage aliquot and store at -20 o C. Avoid freeze/thaw cycles.
|
|
Restrictions
|
For Research Use only
|
|
Publications
|
Suimovua, Kluima, Cermak et al.: "Arf and Rho GAP adapter protein ARAP1 participates in the mobilization of TRAIL-R1/DR4 to the plasma membrane." in: Apoptosis : an international journal on programmed cell death, Vol. 13, Issue 3, pp. 423-36, 2008 (PubMed).
|
Alternatives for antigen "Tumor Necrosis Factor Receptor Superfamily, Member 10a (TNFRSF10A)", type "Antibodies"
|
Hosts
|
Rabbit (19), Mouse (18), Goat (1)
|
|
Reactivities
|
Human (36), Mouse (Murine) (3), Rat (Rattus) (3)
|
|
Applications
|
Western Blotting (WB) (27), Flow Cytometry (FACS) (13), Enzyme Immunoassay (EIA) (8), Immunofluorescence (IF) (7), Immunoprecipitation (IP) (6), Functional Studies (Func) (4), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)) (3), ELISA (2), Immunohistochemistry (IHC) (1)
|
|
Conjugates
|
FITC (2), PE (2)
|
|
Epitopes
|
AA 427-445 (1), C-Term (1), N-Term (1)
|